The listing below shows our latest News Items and is updated regularly. If you wish to post a news item please select the 'Post News' button on the right. The displayed news feed starts on 1st August 2016. Older items can be found here.
To 'Post Your News' use the button at the top right.
We are pleased to present below all posts archived in 'February, 2019'. If you still can't find what you are looking for, try using the search box.
Detachin™ Cell Detachment Solution from AMSBIO is a high-performance alternative to Trypsin/EDTA for detaching adherent cells from in vitro growth vessels. Detachin™ provides rapid, gentle, and effective detachment of a wide variety of adherent cells, including primary cells, from all commercially available tissue culture plasticware.
Read the rest of entry »
27 February 2019: Aston University and University of Birmingham Enterprise have teamed up with Minerva, one of the UK’s largest traditional angel investor networks, to expand the funding opportunities available to start-up businesses in the West Midlands by launching a network of ‘business angels with insight’ for Birmingham.
Oxford, UK, February 20, 2019. Absolute Antibody Ltd., an industry-leading manufacturer of recombinant antibodies, has developed custom protein purification systems to significantly increase its antibody production throughput.
Abingdon, UK; 19th February 2019 - OBN, the Membership organisation supporting the UK’s innovative life sciences companies, is pleased to announce today the launch of its new online Purchasing Platform. The aim of the new Purchasing Platform, which can be accessed by OBN’s Full Members, Sponsors and Supporters, is to enable users to have a better overview and control of spend and save time and money.
Good news! It’s finally here and has been rebranded as Smart Grants. If you’ve been working within the R&D funding world for as long as we have, you will know that a couple of years ago, ‘Smart’ was the name of the Open, so the name may induce a slight feeling of déjà vu!
AMSBIO has established a comprehensive portfolio of knock-out cell lines and lysates generated with CRISPR/Cas9 technology.
Using CRISPR/Cas9 gene editing technology for the generation of knock-out cell lines and cell lysates ensures the development of useful tools to validate antibody specificity and elucidate gene function. Knock-out cell lines and cell lysates are widely agreed to be the best negative controls to quickly and confidently prove an antibody’s specificity for a target of interest and ensure reproducibility.
Oxford, UK – February 12, 2019 – Blue Earth Diagnostics, a leading molecular imaging diagnostics company, today announced that the first commercial production of Axumin® (fluciclovine (18F)) in Italy occurred recently, with the first Italian patients being dosed.
Arecor Ltd, the specialty pharmaceutical company leveraging its innovative and proprietary formulation technology to develop superior treatments for a range of disease areas, including diabetes, is pleased to announce that the Company has been awarded a £0.5 million grant from Innovate UK, the UK’s innovation agency, to advance the Company's proprietary super-fast-acting prandial insulin product, AT270.
AMSBIO is a leading supplier of gold, silver and platinum coated substrates for nanotechnology researchers looking to use these surfaces to characterize self-assembled monolayers using atomic force microscopy (AFM), or scanning tunneling microscopy (STM).
Grey Wolf Therapeutics completes £10 million ($14 million) series A financing with Andera Partners and Canaan to fund development of immuno-oncology therapies to increase tumour visibility
OBN aims to provide sector NEWS that is relevant to our Membership. We filter information from a variety of sources, publish items ourselves and will publish items of News from our Members. Press releases about OBN can be found here.